Published in Blood on February 03, 2005
Historical review: megakaryopoiesis and thrombopoiesis. Blood (2008) 2.03
Recommendations for the transfusion management of patients in the peri-operative period. II. The intra-operative period. Blood Transfus (2011) 1.45
Recommendations for the transfusion of plasma and platelets. Blood Transfus (2009) 1.45
CD8+ T cells mediate antibody-independent platelet clearance in mice. Blood (2016) 1.39
Platelet transfusion in hematology, oncology and surgery. Dtsch Arztebl Int (2014) 1.26
Pathogen Inactivation of Platelet and Plasma Blood Components for Transfusion Using the INTERCEPT Blood System™ Transfus Med Hemother (2011) 1.04
Platelet transfusions: impact on hemostasis, thrombosis, inflammation and clinical outcomes. Thromb Res (2010) 0.97
Extended storage of platelet-rich plasma-prepared platelet concentrates in plasma or Plasmalyte. Transfusion (2010) 0.95
Platelet transfusion - the art and science of compromise. Transfus Med Hemother (2013) 0.94
Leucoreduction of blood components: an effective way to increase blood safety? Blood Transfus (2015) 0.94
Identification of platelet refractoriness in oncohematologic patients. Clinics (Sao Paulo) (2011) 0.94
Transfusion efficacy of apheresis platelet concentrates irradiated at the day of transfusion is significantly superior compared to platelets irradiated in advance. Transfus Med Hemother (2014) 0.92
Hemostatic function and transfusion efficacy of apheresis platelet concentrates treated with gamma irradiation in use for thrombocytopenic patients. Transfus Med Hemother (2014) 0.91
Low-level HLA antibodies do not predict platelet transfusion failure in TRAP study participants. Blood (2013) 0.88
Cross-match-compatible platelets improve corrected count increments in patients who are refractory to randomly selected platelets. Blood Transfus (2013) 0.87
A general change of the platelet transfusion policy from apheresis platelet concentrates to pooled platelet concentrates is associated with a sharp increase in donor exposure and infection rates. Transfus Med Hemother (2008) 0.85
Platelet transfusion - the new immunology of an old therapy. Front Immunol (2015) 0.84
Anti-HLA alloantibodies in surgical patients refractory to platelet transfusion. Am J Hematol (2014) 0.84
Transfusion medicine problems and solutions for the pediatric hematologist/oncologist. Pediatr Blood Cancer (2012) 0.84
Agreement among HLA antibody detection assays is higher in ever-pregnant donors and improved using a consensus cutoff. Transfusion (2010) 0.84
Understanding loss of donor white blood cell immunogenicity after pathogen reduction: mechanisms of action in ultraviolet illumination and riboflavin treatment. Transfusion (2009) 0.82
Pathophysiology and management of thrombocytopenia in bone marrow failure: possible clinical applications of TPO receptor agonists in aplastic anemia and myelodysplastic syndromes. Int J Hematol (2013) 0.82
Persistence of lymphocytotoxic antibodies in patients in the trial to reduce alloimmunization to platelets: implications for using modified blood products. Transfus Med Rev (2011) 0.81
Comparison of different platelet count thresholds to guide administration of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation. Cochrane Database Syst Rev (2015) 0.80
Platelet storage and transfusions: new concerns associated with an old therapy. Drug Discov Today Dis Mech (2011) 0.80
Platelet transfusions in cancer patients with hypoproliferative thrombocytopenia in the intensive care unit. Ann Intensive Care (2015) 0.79
Leukoreduction and ultraviolet treatment reduce both the magnitude and the duration of the HLA antibody response. Transfusion (2013) 0.78
Detection and Identification of Platelet-Associated Alloantibodies by a Solid-Phase Modified Antigen Capture Elisa (MACE) Technique and Its Correlation to Platelet Refractoriness in Multi platelet Concentrate Transfused Patients. Indian J Hematol Blood Transfus (2014) 0.78
Different doses of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation. Cochrane Database Syst Rev (2015) 0.77
A therapeutic-only versus prophylactic platelet transfusion strategy for preventing bleeding in patients with haematological disorders after chemotherapy or stem cell transplantation. Cochrane Database Syst Rev (2014) 0.77
Alternative agents versus prophylactic platelet transfusion for preventing bleeding in patients with haematological disorders after chemotherapy or stem cell transplantation. Cochrane Database Syst Rev (2015) 0.77
Antifibrinolytics (lysine analogues) for the prevention of bleeding in people with haematological disorders. Cochrane Database Syst Rev (2016) 0.76
Alternatives, and adjuncts, to prophylactic platelet transfusion for people with haematological malignancies undergoing intensive chemotherapy or stem cell transplantation. Cochrane Database Syst Rev (2016) 0.76
Supportive care in patients with acute leukaemia: historical perspectives. Blood Transfus (2014) 0.76
Comparison of different platelet count thresholds to guide administration of prophylactic platelet transfusion for preventing bleeding in patients with haematological disorders after chemotherapy or stem cell transplantation. Cochrane Database Syst Rev (2014) 0.76
A therapeutic-only versus prophylactic platelet transfusion strategy for preventing bleeding in patients with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation. Cochrane Database Syst Rev (2015) 0.76
Different doses of prophylactic platelet transfusion for preventing bleeding in patients with haematological disorders after chemotherapy or stem cell transplantation. Cochrane Database Syst Rev (2014) 0.76
Comparison of a therapeutic-only versus prophylactic platelet transfusion policy for people with congenital or acquired bone marrow failure disorders. Cochrane Database Syst Rev (2016) 0.75
Prevalence of platelet reactive antibodies in patient's refractory to platelet transfusions. Asian J Transfus Sci (2014) 0.75
The Blood Group A Genotype Determines the Level of Expression of the Blood Group A on Platelets But Not the Anti-B Isotiter. Transfus Med Hemother (2015) 0.75
Determination of an unrelated donor pool size for human leukocyte antigen-matched platelets in Brazil. Rev Bras Hematol Hemoter (2015) 0.75
Italian daily platelet transfusion practice for haematological patients undergoing high dose chemotherapy with or without stem cell transplantation: a survey by the GIMEMA Haemostasis and Thrombosis Working Party. Blood Transfus (2016) 0.75
Efficiency of treatment with rituximab in platelet transfusion refractoriness: a study of 7 cases. Int J Clin Exp Med (2015) 0.75
Efficacy and Adverse Events of Platelet Transfusion Product-Specific Differences. Transfus Med Hemother (2008) 0.75
Assessing Safety of Pneumatic Tube System (PTS) for Patients with Very Low Hematologic Parameters. Med Sci Monit (2016) 0.75
Indications for platelet transfusion in patients with thrombocytopenia. Blood Transfus (2014) 0.75
Comments on: Frequency of human platelet antigens in oncohematological patients with thrombocytopenia and the probability of incompatibility to platelet transfusions. Rev Bras Hematol Hemoter (2012) 0.75
Evaluation of transfusion pyrexia: a review of differential diagnosis and management. ISRN Hematol (2012) 0.75
Could Microparticles Be the Universal Quality Indicator for Platelet Viability and Function? J Blood Transfus (2016) 0.75
2 Platelet Concentrates. Transfus Med Hemother (2009) 0.75
Reduced MHC alloimmunization and partial tolerance protection with pathogen reduction of whole blood. Transfusion (2016) 0.75
Prevalence of risk factors for platelet transfusion refractoriness in multitransfused hemato-oncological patients at tertiary care center in North India. Asian J Transfus Sci (2015) 0.75
Intracranial haemorrhage in thrombocytopenic haematology patients--a nested case-control study: the InCiTe study protocol. BMJ Open (2014) 0.75
Assessment of the Clinical Performance of Platelet Concentrates Treated by Pathogen Reduction Technology in Santiago de Compostela. Transfus Med Hemother (2016) 0.75
Bleeding After Endoscopic Procedures in Patients With Chronic Hematologic Thrombocytopenia. Dig Dis Sci (2016) 0.75
Microdroplet testing for HLA-A, -B, -C, and -D antigens. The Phillip Levine Award Lecture. Am J Clin Pathol (1978) 6.88
Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. The Trial to Reduce Alloimmunization to Platelets Study Group. N Engl J Med (1997) 4.44
An alloimmunized, thrombocytopenic patient successfully transfused with acid-treated, random-donor platelets. Br J Haematol (1991) 2.74
The effects of irradiation on blood components. Transfusion (1981) 1.40
Effect of anticoagulant and ABO incompatibility on recovery of transfused human platelets. Blood (1965) 1.28
Platelet kinetics in patients with bone marrow hypoplasia: evidence for a fixed platelet requirement. Blood (1985) 1.18
Corrected count increment and percent platelet recovery as measures of posttransfusion platelet response: problems and a solution. Transfusion (1999) 1.13
Factors associated with response to platelet transfusion following hematopoietic stem cell transplantation. Bone Marrow Transplant (1996) 1.04
Platelet transfusion The selection of compatible platelet donors for refractory patients by lymphocyte HL-A typing. N Engl J Med (1969) 1.03
Relative importance of immune and non-immune causes of platelet refractoriness. Vox Sang (1994) 1.01
Clinical and blood bank factors in the management of platelet refractoriness and alloimmunization. Blood (1993) 1.00
Factors influencing the transfusion response to HLA-selected apheresis donor platelets in patients refractory to random platelet concentrates. Br J Haematol (1989) 0.98
Antigenic specificity of antibody reactive in the antiglobulin-augmented lymphocytotoxicity test. Transplantation (1982) 0.95
Clinical and laboratory factors associated with platelet transfusion refractoriness: a case-control study. Br J Haematol (1996) 0.94
Effect of storage time on clinical efficacy of single-donor platelet units. Transfusion (1993) 0.93
Storage of apheresis platelets after gamma radiation. Transfusion (1994) 0.92
Clinical factors influencing the efficacy of pooled platelet transfusions. Blood (1988) 0.91
Viability of platelets following storage in the irradiated state. A pair-controlled study. Transfusion (1988) 0.90
Influence of clinical status on the efficiency of stored platelet transfusion. Br J Haematol (1994) 0.89
Platelet storage for 7 days in second-generation blood bags. Transfusion (1986) 0.88
Platelet production in the Old World--and the New. Transfusion (1996) 0.88
Clinical evaluation of the effects of storage time and irradiation on transfused platelets. Vox Sang (1991) 0.87
The role of the spleen in thrombokinetics. J Lab Clin Med (1971) 0.86
Ultraviolet B-induced loss of HLA class II antigen expression on lymphocytes is dose, time, and locus dependent. Exp Hematol (1990) 0.82
Transfusion experience with platelet concentrates stored for 24 to 72 hours at 22 degrees C. Importance of storage time. Transfusion (1982) 0.82
Comparison of posttransfusion recoveries achieved with either fresh or stored platelet concentrates. Blut (1987) 0.81
The effects of splenectomy on engraftment and platelet transfusion requirements in patients with chronic myelogenous leukemia undergoing marrow transplantation. Am J Hematol (1986) 0.81
Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol (2003) 17.67
2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol (2006) 11.26
Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol (2002) 9.83
Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood (2006) 8.33
Dose of prophylactic platelet transfusions and prevention of hemorrhage. N Engl J Med (2010) 5.23
Toward an understanding of transfusion-related acute lung injury: statement of a consensus panel. Transfusion (2004) 4.48
Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood (2002) 4.00
Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood (2002) 3.60
Differences in outcome in adolescents with acute lymphoblastic leukemia: a consequence of better regimens? Better doctors? Both? J Clin Oncol (2003) 3.50
Flexible, foldable, actively multiplexed, high-density electrode array for mapping brain activity in vivo. Nat Neurosci (2011) 3.03
Effects of red-cell storage duration on patients undergoing cardiac surgery. N Engl J Med (2015) 3.03
Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood (2007) 2.80
Therapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: results of an intergroup study, cancer and leukemia group B 9011. J Clin Oncol (2002) 2.74
Positive and negative network correlations in temporal lobe epilepsy. Cereb Cortex (2004) 2.73
Platelet transfusion: a clinical practice guideline from the AABB. Ann Intern Med (2014) 2.63
A single-dose study of denosumab in patients with various degrees of renal impairment. J Bone Miner Res (2012) 2.43
A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood (2002) 2.33
Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study. J Clin Oncol (2005) 2.16
Acute myeloid leukaemia in adults. Lancet (2013) 2.15
All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol. Blood (2002) 2.11
The big picture on nanomedicine: the state of investigational and approved nanomedicine products. Nanomedicine (2012) 1.83
Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study. J Clin Oncol (2002) 1.80
The effect of imatinib mesylate on patients with Philadelphia chromosome-positive chronic myeloid leukemia with secondary chromosomal aberrations. Clin Cancer Res (2003) 1.78
Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial. Blood (2002) 1.71
Inhibition of sclerostin by monoclonal antibody enhances bone healing and improves bone density and strength of nonfractured bones. J Bone Miner Res (2011) 1.70
High-mannose glycans on the Fc region of therapeutic IgG antibodies increase serum clearance in humans. Glycobiology (2011) 1.68
Breast implant infections: is cefazolin enough? Plast Reconstr Surg (2010) 1.67
Anticoagulation monitoring during pediatric extracorporeal membrane oxygenation. ASAIO J (2012) 1.65
Effects of granulocyte-colony stimulating factor on chromosome aneuploidy and replication asynchrony in healthy peripheral blood stem cell donors. Blood (2011) 1.60
Therapy-related myeloid leukemia after treatment for epithelial ovarian carcinoma: an epidemiological analysis. Gynecol Oncol (2011) 1.58
Gemtuzumab ozogamicin: time to resurrect? J Clin Oncol (2012) 1.57
Distinct genetic alterations in colorectal cancer. PLoS One (2010) 1.56
Good manufacturing practices production of natural killer cells for immunotherapy: a six-year single-institution experience. Transfusion (2007) 1.49
The United States' potential blood donor pool: estimating the prevalence of donor-exclusion factors on the pool of potential donors. Transfusion (2007) 1.44
The cost-effectiveness of platelet additive solution to prevent allergic transfusion reactions. Transfusion (2013) 1.43
Platelets photochemically treated with amotosalen HCl and ultraviolet A light correct prolonged bleeding times in patients with thrombocytopenia. Transfusion (2006) 1.41
Symptomatic BK virus reactivation following fludarabine, cyclophosphamide and rituximab chemotherapy for chronic lymphocytic leukemia/small lymphocytic lymphoma. Leuk Lymphoma (2013) 1.40
Cell loss and recovery in umbilical cord blood processing: a comparison of postthaw and postwash samples. Transfusion (2005) 1.39
Identification of novel mutations by exome sequencing in African American colorectal cancer patients. Cancer (2014) 1.39
Very late recurrences of leukemia: why does leukemia awake after many years of dormancy? Leuk Res (2011) 1.39
Correspondence. Retina (2017) 1.38
The effect of dose increase of imatinib mesylate in patients with chronic or accelerated phase chronic myelogenous leukemia with inadequate hematologic or cytogenetic response to initial treatment. Clin Cancer Res (2003) 1.34
Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a cancer and leukemia group B study. J Clin Oncol (2004) 1.32
Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial. Blood (2004) 1.31
Molecular cloning and characterization of a novel gene family of four ancient conserved domain proteins (ACDP). Gene (2003) 1.31
Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study. Blood (2014) 1.30
Metabolic impact of sex hormones on obesity. Brain Res (2010) 1.30
SCD1 inhibition causes cancer cell death by depleting mono-unsaturated fatty acids. PLoS One (2012) 1.29
Impact of BRAF, MLH1 on the incidence of microsatellite instability high colorectal cancer in populations based study. Mol Cancer (2008) 1.27
The combination of colistin and doripenem is synergistic against Klebsiella pneumoniae at multiple inocula and suppresses colistin resistance in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother (2012) 1.25
Using lean techniques to define the platelet (PLT) transfusion process and cost-effectiveness to evaluate PLT dose transfusion strategies. Transfusion (2012) 1.24
Differences in prognostic factors and outcomes in African Americans and whites with acute myeloid leukemia. Blood (2004) 1.20
The osteo-odonto-keratoprosthesis (OOKP). Semin Ophthalmol (2005) 1.18
Observing and engaging in purposeful actions with objects influences estimates of their size. Percept Psychophys (2004) 1.18
Intensive chemotherapy with and without cranial radiation for Burkitt leukemia and lymphoma: final results of Cancer and Leukemia Group B Study 9251. Cancer (2004) 1.18
TDP-43, an ALS linked protein, regulates fat deposition and glucose homeostasis. PLoS One (2013) 1.14
Patient care during infusion of hematopoietic progenitor cells. Transfusion (2004) 1.10
Factors influencing moderate to severe reactions to PLT transfusions: experience of the TRAP multicenter clinical trial. Transfusion (2003) 1.09
New low-frequency platelet glycoprotein polymorphisms associated with neonatal alloimmune thrombocytopenia. Transfusion (2009) 1.07
Marrow failure. Hematology Am Soc Hematol Educ Program (2004) 1.06
Dickkopf-1 regulates bone formation in young growing rodents and upon traumatic injury. J Bone Miner Res (2011) 1.05
Status of blood banking and the blood supply in Afghanistan. Transfusion (2009) 1.04
Induced pluripotent stem cell therapies for retinal disease. Curr Opin Neurol (2010) 1.03
Analysis of age, estimated creatinine clearance and pretreatment hematologic parameters as predictors of fludarabine toxicity in patients treated for chronic lymphocytic leukemia: a CALGB (9011) coordinated intergroup study. Cancer Chemother Pharmacol (2002) 1.02
Genomic aberrations in an African American colorectal cancer cohort reveals a MSI-specific profile and chromosome X amplification in male patients. PLoS One (2012) 1.02
Molecular transfer of CD40 and OX40 ligands to leukemic human B cells induces expansion of autologous tumor-reactive cytotoxic T lymphocytes. Blood (2004) 1.02
"I am older, not elderly," said the patient with acute myeloid leukemia. J Clin Oncol (2009) 1.02
SLC5A8 gene, a transporter of butyrate: a gut flora metabolite, is frequently methylated in African American colon adenomas. PLoS One (2011) 1.00
HLA mismatching within or outside of cross-reactive groups (CREGs) is associated with similar outcomes after unrelated hematopoietic stem cell transplantation. Blood (2007) 1.00
A phased consent policy for cord blood donation. Transfusion (2002) 1.00
Toward a comprehensive and systematic methylome signature in colorectal cancers. Epigenetics (2013) 1.00
Postremission therapy with low-dose interleukin 2 with or without intermediate pulse dose interleukin 2 therapy is well tolerated in elderly patients with acute myeloid leukemia: Cancer and Leukemia Group B study 9420. Clin Cancer Res (2002) 1.00
Increased callus mass and enhanced strength during fracture healing in mice lacking the sclerostin gene. Bone (2011) 1.00
Guidelines for the diagnosis and management of adult myelodysplastic syndromes. Br J Haematol (2013) 0.99
Flow-through flaps: a review of current knowledge and a novel classification system. Microsurgery (2006) 0.99
Reconstruction of the lateral mandibulectomy defect: management based on prognosis and location and volume of soft tissue resection. Laryngoscope (2006) 0.98
Aesthetic skin branding: a novel form of body art with adverse clinical sequela. J Burn Care Res (2006) 0.98
A 50-year review of colorectal cancer in African Americans: implications for prevention and treatment. Dig Dis Sci (2009) 0.97
A single dose of rasburicase is sufficient for the treatment of hyperuricemia in patients receiving chemotherapy. Leuk Res (2004) 0.97
Validation and diagnostic accuracy of the Alzheimer's questionnaire. Age Ageing (2012) 0.94
The Alzheimer's questionnaire: a proof of concept study for a new informant-based dementia assessment. J Alzheimers Dis (2010) 0.94
Platelet utilization and the transfusion trigger: a prospective analysis. Transfusion (2007) 0.94
Impact of donor- and collection-related variables on product quality in ex utero cord blood banking. Transfusion (2005) 0.93
Improving fat transfer viability: the role of aging, body mass index, and harvest site. Plast Reconstr Surg (2014) 0.93
A fluorescence resonance energy transfer activation sensor for Arf6. Anal Biochem (2007) 0.93
Standardization of bleeding assessment in immune thrombocytopenia: report from the International Working Group. Blood (2013) 0.93
Effect of CXC chemokine platelet factor 4 on differentiation and function of monocyte-derived dendritic cells. Int Immunol (2003) 0.93
Improvement of pulmonary function with imatinib mesylate in bronchiolitis obliterans following allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant (2006) 0.93
Prevalence of colorectal neoplasia among young African Americans and Hispanic Americans. Dig Dis Sci (2013) 0.93